Addition of carboplatin to standard neoadjuvant anthracycline- and taxane-based chemotherapy has been shown to improve pCR rate in patients with HER2-negative breast cancer [29] or TNBC [8, 30, 31]. The gene discussed is ERBB2; the disease is breast carcinoma.